Corvus Announces Upcoming CPI-818 Data Presentations at the American Society of Hematology (ASH) Annual Meeting & ExpositionGlobeNewsWire • 11/30/20
Corvus Hosting R&D Symposium on November 12 to Highlight COVID-19 Program and Updated Study Data Presented at SITC Annual MeetingGlobeNewsWire • 11/11/20
Corvus Completes Enrollment in Phase 1 Study of CPI-006 for Patients with COVID-19 and Presents Study Data at 2020 Society for Immunotherapy of Cancer (SITC) Annual MeetingGlobeNewsWire • 11/09/20
Corvus Pharmaceuticals to Present Updated Data from its Clinical Trial of CPI-006 for Patients with COVID-19 at the 2020 Society for Immunotherapy of Cancer (SITC) Annual MeetingGlobeNewsWire • 10/29/20
Corvus Pharmaceuticals Announces Co-Founding of Angel Pharmaceuticals in ChinaGlobeNewsWire • 10/05/20
New Data from Corvus Phase 1 Study of CPI-006 Continues to Support its Potential as a Treatment for COVID-19GlobeNewsWire • 10/05/20
New Data from Ciforadenant Phase 1b/2 Clinical Study Presented at ESMO Virtual Congress 2020GlobeNewsWire • 09/17/20
Corvus Pharmaceuticals Provides Update on Clinical Trial of CPI-006 for Patients with COVID-19GlobeNewsWire • 09/10/20
Corvus Pharmaceuticals to Present at the 2020 Wedbush PacGrow Healthcare Virtual ConferenceGlobeNewsWire • 08/04/20
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial ResultsGlobeNewsWire • 07/30/20
Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter 2020 Financial Results on July 30, 2020GlobeNewsWire • 07/23/20
Corvus Gold Announces Brand New Oxide Gold Discovery at the Lynnda Strip Target, 2.5 kilometres North of the Mother Lode Deposit with 44m @ 0.90 g/t Gold and 20m @ 0.74 g/t Gold within 197m @ 0.44 g/t GoldGlobeNewsWire • 07/16/20
Corvus Pharmaceuticals Initiates Clinical Trial of Novel Immunotherapy for Patients with COVID-19GlobeNewsWire • 07/07/20
Corvus Pharmaceuticals Presents Updated Clinical Data Supporting and Refining the Adenosine Gene Signature’s Ability to Identify Patients Likely to Respond to Treatment with CiforadenantGlobeNewsWire • 05/29/20
Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard Miller on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/02/20